Parnassus Investments LLC Sells 105,080 Shares of Hologic, Inc. (NASDAQ:HOLX)

Parnassus Investments LLC decreased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 8.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,168,749 shares of the medical equipment provider’s stock after selling 105,080 shares during the quarter. Parnassus Investments LLC owned 0.50% of Hologic worth $95,206,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in HOLX. Innealta Capital LLC acquired a new stake in shares of Hologic during the 2nd quarter worth approximately $25,000. Wolff Wiese Magana LLC acquired a new stake in shares of Hologic during the 3rd quarter valued at about $25,000. iA Global Asset Management Inc. acquired a new position in Hologic in the first quarter worth about $37,000. Sunbelt Securities Inc. bought a new position in Hologic during the second quarter worth about $37,000. Finally, Cromwell Holdings LLC boosted its holdings in Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 416 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on HOLX. JPMorgan Chase & Co. raised their target price on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. UBS Group increased their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Royal Bank of Canada upped their price objective on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. Leerink Partners reduced their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, Raymond James increased their target price on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $89.91.

Hologic Price Performance

Shares of HOLX stock opened at $78.79 on Tuesday. The firm’s 50 day moving average price is $80.63 and its two-hundred day moving average price is $78.28. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic, Inc. has a 52-week low of $67.59 and a 52-week high of $84.67. The stock has a market cap of $18.30 billion, a PE ratio of 23.66, a PEG ratio of 2.48 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same quarter in the prior year, the company posted $0.89 earnings per share. The firm’s revenue was up 4.5% on a year-over-year basis. As a group, analysts forecast that Hologic, Inc. will post 4.27 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.